SELF MANAGED ABORTION - A REALITY? LONG WAY TO GO.
|
|
- Abner Cook
- 8 years ago
- Views:
Transcription
1 REVIEW ARTICLE SELF MANAGED ABORTION - A REALITY? LONG WAY TO GO. S.CHHABRA*, S. KARAPATE**, S.CHOPRA*** Women of all walks of life use safe / unsafe means of abortions to eliminate unwanted pregnancies. In India around 80% of pregnancies are unplanned and 30% unwanted, so the need for abortions is always there and the resultant clandestine abortions continue to be one of the major causes of maternal deaths. Some 70,000 women die of unsafe abortions annually, making it one of the leading causes of maternal mortality (13%) 1. Further five million women suffer temporary or permanent disability, even when abortion is performed at safe places. This is so because surgical abortion could result in cardiac arrest, hemorrhage, uterine perforation and infection. Studies show increased psychological problems with surgical abortion including posttraumatic stress disorder. Embolism and infection have decreased over the years but complications related to anesthesia continue. So, there has been a constant endeavor to have safe, simple, effective and cheap *Director & Prof.,**Ex Postgraduate, ***Postgraduate, Dept. of Obstetrics and Gynecology, MGIMS, Sevagram methods. Since years various drugs have been tried, some continue to be used, some not so, because of side effects. 1 PROSTAGLANDINS During the 1970s natural prostaglandins, PGE1 and PGF2 were used to induce early abortion effectively with transcervical or vaginal administration 2. By 1980 more stable analogues, including Gemeprost and the injectable analogue sulprostone were introduced, but have been abandoned because of side effects. Misoprostol, an orally-active synthetic analogue, derivative of prostaglandin E1 FDA approved for the prevention of gastric ulcers caused by non-steroidal anti-inflammatory drugs, has been tried to induce abortion. Now there is enough evidence of its safety and effectiveness when used alone or in combination with mifepristone, with complete abortion rates of 95% to 97% 3,4. It can be given sublingually, orally, vaginally or rectally; can be stored at room temperature and is cheap.
2 There are reports that intravaginal route is more effective than oral because of three times higher bioavailability. In a study it was observed that complete expulsion rate was 95% with vaginal route and 87% with oral.3 However the efficacy of vaginal misoprostol in the first trimester varies widely from 47 to 97% 4 because it is absorbed at different rates, is cumbersome with possibility of local changes and hemorrhage. 2 OTHERS Mifepristone(RU 486) is an antiprogestin analogue of norethindrone, with strong affinity for the progesterone receptors and acts as an antagonist, blocking the effects of natural progesterone in cases of amenorrhora of less than 50 days. This synthetic steroid has been marketed in France as an abortifacient since In Europe and China, millions of women have received mifepristone in doses of 1400 to 1600mg administered over 1-10 days for gestation upto 49 days, with complete abortion rates of 64% to 85%.With the lower doses, the number of ongoing pregnancies was much higher (26% with the dose of 200 mg). 4 Review done by Henderson6 has reported that the safety of mifepristone is high and few serious medical complications occur in routine clinical use. Methotrexate in low dose used for extrauterine pregnancy, gestational trophoblastic neoplasia and was believed to be a potential agent for successful abortion because of its direct cytotoxic hydrofolate reductase inhibitor action on the trophoblastic tissue which decreases the production of human chorionic gonadotrophin. Iamakov et al 7 have reported that methotrexate and misoprostol both are effective and can be offered, however with methotrexate bleeding does not begin until many days after treatment and it is a potentially toxic drug. Tamoxifen, a selective estrogen receptor modulator has been tried to induce abortion. It interferes with continuation of pregnancy by modulation of estrogen receptors, however used alone, it has shown poor success. 3 COMBINATIONS The efficacy of prostaglandins to complement the antiprogesterone effect of mifeprostone for termination of early pregnancy is well established. All three prostaglandin analogues have been used in combination with mifepristone for early abortion. A study carried out in France revealed the safety and efficacy of Mifepristone and Misoprostol combination with a success rate of 92.4%. 8
3 The recommended regimen for abortion of less than 7 weeks (49 days) gestation is oral mifepristone 200 mg followed by vaginal misoprostol 800 mcg after hours 9 however it has been reported that the interval between mifepristone and misoprostol can be decreased to 6-8 hours without loss of efficacy 10. Home administration of misoprostol is safe and feasible. In trials of less than 9 weeks gestation it was revealed that a lower dose of mifepristone, 200 mg is as effective as the 600 mg when combined with a prostaglandin analogues 11, but efficacy declines from 97% to 89% if the gestation is 64 days or more 12. Ngai 13 has found that addition of water increases the abortion rate from 65% to 85%. Reports vary in efficacy. In one study with mifepristone (400 mg) and misoprostol (800 mcg), administered vaginally, the complete abortion rate was only 61% 11. Liao et al 14 have reported that 75 mg mifepristone in capsule form combined with 600 mcg misoprostol is as effective as 150 mg mifepristone in tablet form up to 49 days of pregnancy. Buccal administration of misoprostol after low dose mifepristone is highly effective and acceptable alternative compared with vaginal administration in pregnancies of 56 days 15. While success of surgical abortion is 98-99%, combination of methotrexate with misoprostol gives % and mifepristone and misoprostol 94-99% success. In a study by Banerjee et al 16, women with pregnancy duration of 56 days or less received 200mg mifepristone followed by inclinic adminis tration of 400mcg misoprostol, orally in Delhi and sublingually in Kolkata, successful medical abortion occurred in 92.5% and 99.3% of women respectively. Crenin 17 evaluated oral methotrexate 25 mg and 50 mg with vaginal misoprostol of 800 mcg, repeated 1-2 days later if the pregnancy had not been expelled, although not statistically significant, the pregnancy passed within 24 hrs of the first or second dose of misoprostol, more often with 50 mg than with 25 mg. Mitchell9 reported 3% failures (need of surgical abortion for continuing viable pregnancy) for 49 days gestation or less and 12% for days. Tamoxifen has been reported to be effective at a dose of 20mg orally once a day for 4 days followed by 800mcg of misoprostol intravaginal, at gestation less than 56 days with complete abortion in 92%. 18 MEDICALLY ADDED SURGICAL PROCEDURE Earlier the most commonly used methods of cervical dilation like intracervical tents, Isapgol husk, laminaria tent; are not used nowadays.
4 Mifepristone, Gemeprost and misoprostol have all shown to be effective for pre-operative cervical dilatation. Misoprostol 400 mcg 2-4 hour before vaccum aspiration given either vaginally or orally gives satisfactory results. Higher doses of misoprostol (600 and 800 mcg) achieve the desired successful cervical dilation of 8 mm or more with a shorter evacuation interval of 2 hours compared with 400 mcg but have more side effects including abdominal pain and fever. 19 ADVANTAGES OF MEDICAL ABORTION Medical abortion is more private, thus more acceptable in situations where social stigma is attached to induced abortion, also it is feasible and safe in situations where trained manpower and surgical facilities are insufficient overcoming the serious complications associated with surgical methods and there is no effect on future fertility like infertility, ectopic gestation, recurrent spontaneous abortion, preterm labour, and reduced birth weight. However surgical backup is essential. CONTRAINDICATIONS TO MEDICAL ABORTION Women with confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass, chronic adrenal failure, history of allergy to medications, haemorrhagic disorders or concurrent anticoagulant therapy, inherited porphyrias, should not be subjected to medical abortion and also it should not be done if there is no access to medical facilities equipped to provide emergency treatment of incomplete abortion, blood transfusion and emergency resuscitation. COMPLICATIONS With medical means of abortion side effects like nausea, vomiting and / or diarrhea are usually self limiting. Some women will require surgical procedure for control of bleeding, resolution of incomplete expulsion or termination of continuing pregnancy. In the study by Creinin 20, the incidence of vomiting, bleeding spotting in women who received misoprostol on the same day as mifepristone were significantly less compared with women who received misoprostol 24 hours after the mifepristone. Gastrointestinal side effects are less severe with the analogues than with natural prostaglandins. Some report that the side effects are significantly less with vaginal route. Compared with surgical termination, medical abortion is associated with a lower risk of pelvic inflammatory disease. The frequency of failure after medical abortion, followed by subsequent surgical intervention, is 2 to 6% in cases of mifepristone with vaginal prostaglandin analogue. 21 Winikoff et al 22 have
5 reported that in general, failure rates reported with medical and surgical abortion were 8.6% and 0.4% respectively in China and 16.0% and 4.0% in Cuba and 5.2% and 0% in India These researchers have concluded that although the failure rates for medical abortion were much more (5-16%) than those of surgical abortion (0-4.0%).Women were satisfied with either method but preferred medical abortion. More than 40% of the women whose medical abortion failed stated that they would have a surgical procedure for a subsequent abortion compared with <3% of the women who had a successful termination. Extra visits, blood tests and lack of emotional support at home may be deterrent. In most acceptability surveys the best feature has been avoidance of a surgical procedure and worst features were uncertainty and fear of side effects. Early REFERENCES : ectopic pregnancy was difficult to detect and possible occurrence makes a follow up visit 8-15 days mandatory. If pregnancy continues congenital anomalies are a concern. There is no teratogenic effect of mifepristone. Methotrexate causes fetal anomalies in higher doses and reports after low dose are sparse. Misoprostol causes mild uterine contractions resulting in decreased blood flow leading to possibilities of congenital malformations in case the pregnancy continues. Educational initiatives are needed to help clinicians to overcome any barriers and to actualize potential medical abortion in women's health care with clear knowledge of advantages and disadvantages Mocsary P Csapo AJ. Menstrual induction with PGF2a and PGE2 Prostagladins, 1975; 10: Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception. 2001; 64(2): Schaff EA, Fielding SL, Westhoff C, Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception. 2002; 66(4): Silvestre L, Dubois C, Renault M, Rezvane Y. Baulieu EE, Ulmann A : Voluntary intervention of pregnancy with mifepristone (RU 486) and a Prostaglandin analogue 'A' large scale French experience. N. Eng J Med 1990;8,322(10): Henderson J, Hwang A., Cynthia C. Safety of mifepristone abortions in clinical use. Contraception 2005; 72: Lamakov K, Pekhivanov B., Amallev I., Medical abortion using methotrexate And misoprostol. Efficacy and tolerability. Akush Ginekol (Sofiia) 2005; 44 (3):16-18
6 8 Largeaud M, EI Guindi W, Perotti F, Montoya Y, Caries G, Seve B. Medical termination of pregnancy at 9-14 weeks gestation Prospective study of 105 cases in Saint-Laurent-du-Maronl (French Guyana). J Gynecol Obstet Biol Reprod ( Paris) 2004;33(2): Mitchell D, Creimin, Jill L, Schwartz, Helen CP, Wendy F. Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy report of a randomised trial. Br J Obstet Gynaecol 2001; 108: Schaff E. Evidence for shortening the time interval of prostaglandin after mifepristone for medical abortion. Contraception 2006 ;74: Sharma S, EI-Refaev H, Mitchel H, Ozturk O, Rodeck C. Mifepristone vaginally in an early medical abortion regimen : a pilot study. Contraception 2006, 73(3): Bracken H, Ngoc NT, Schaff E, Coyaji K, Ambardekar S, Westheimer E, Winikoff B. Mifepristone followed in 24 hours to 48 hours by misoprostol for Late first trimester abortion. Obstet Gynecol. 2007; 109(4): Ngai SW vaginal misoprostol alone for medical abortion up to 9 wks of gestation: efficacy and acceptability. Hum reprod ; 15: Liao All, Han XJ, Wu SY, Xiao DZh, Xtong CL, Wu XR. Randomized, double-blind controlled trail of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion. Eur J. Obstet Gynecol Reprod Biol 2001; 116 (2): Schaff E, Middleton T., Randomized trial of mifepristone and buccal or Vaginal misoprostol for abortion through 56 days of last menstrual period. Contaception 2005 ;72: Banerjee A, Anand A, Elul B, Kalyanwala S. Mifepristone-misoprostol abortion in free standing reproductive health clinics in India. J Obstet Gynaecol India 2009; 59(5) : Crenin MD, Vithinghoff E, Keder L. Methotrexate and Misoprostol for early Abortion: a multicentric trial, safety and efficacy. Contraception 1996; 53: Mishell DR Jr. Jain JK, Byrne JD, Lacarra MD. A medical method of early pregnancy termination using tamoxifen and misoprostol. Contraception 1998; 58 (1): Singh K, Fong YF, Prasad RN, Dong E, Evacuation interval after vaginal misoprostol for preabortional cervical priming a randomized trial, Obstet Gynecol ; 94(3): Creinin MD, Shreiber CA, Bednarek P, Lintu H, Wagner MS, Mevn LA. Medical Abortion at the same time ( MAST) study trial group. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion : randomized controlled trial. Obstet Gynecol 2007; 109(4): Schaff EA, Fielding SL, Westhoff C,Charlotte E, Steven H., Lisa S.Vaginal misoprostol administered 1,2, or 3 days after mifepristone for early medical abortion: a randomized trial. J Am Med Assoc 2000; 284, Winikoff B. Sivin I, Coyaji KJ, Cabezas E, Xiao B, Gu S, Du MK, Krishna O R, Eschen A, Ellerton C. Safety efficacy accessibility of medical abortion In China mifepristone misoprostol versus surgical abortion. Am. J. Obst Gynaecol 1997 ;176(2):
Comparison of oral versus vaginal misoprostol & continued use of misoprostol after mifepristone for early medical abortion
Indian J Med Res 122, August 2005, pp 132-136 Comparison of oral versus vaginal misoprostol & continued use of misoprostol after mifepristone for early medical abortion Suneeta Mittal, Sonika Agarwal,
More informationFrequently Asked Questions
Frequently Asked Questions What is Medabon? Medabon is a combination therapy for medical abortion. Medical abortion refers to the process of ending a pregnancy by taking medication, rather than through
More informationIMAP Statement on Safe Abortion
International Planned Parenthood Federation IMAP Statement on Safe Abortion Key points: When performed early in pregnancy by trained health personnel in adequate facilities, abortion is a very safe procedure
More informationAnnotated Bibliography on Misoprostol Alone for Early Abortion
Annotated Bibliography on Misoprostol Alone for Early Abortion 1. Carbonell JL, Rodriguez J, Velazco A, Tanda R, Sanchez C, Barambio S, Chami S, Valero F, Mari J, de Vargas F, Salvador I. Oral and vaginal
More informationClinical Interruption of Pregnancy (Medical/Surgical Abortion)
Clinical Interruption of Pregnancy (Medical/Surgical Abortion) Approximately one fifth of all pregnancies in the United States end in abortion (Ventura et al., 2009). According to the CDC (2011a), there
More informationAlternatives to mifepristone for early medical abortion
International Journal of Gynecology and Obstetrics (2007) 96, 212 218 available at www.sciencedirect.com www.elsevier.com/locate/ijgo SPECIAL ARTICLE Alternatives to mifepristone for early medical abortion
More informationKeywords: Efficacy, Misoprostol Vaginal Administration, Pregnancy
A COMPARISON OF EFFICACY AND SIDE-EFFECTS OF TWO METHODS OF VAGINAL MISOPROSTOL ADMINISTRATION IN THE FIRST TRIMESTER OF PREGNANCY TERMINATION FOR PATIENTS OF BANDARABAS HOSPITAL LOCATED IN IRAN *Azadeaskari,
More informationUpdate on Medical Abortion. P.C. Ho Department of O&G University of Hong Kong IWAC 2013 Bangkok
Update on Medical Abortion P.C. Ho Department of O&G University of Hong Kong IWAC 2013 Bangkok Mifepristone (RU486) Orally active progesterone antagonist at receptor level 97-98% bound to albumin and alpha-1
More informationm e d i c a l a b o r t i o n
providing m e d i c a l a b o r t i o n in l o w-resource settings An Introductory guidebook Second Edition p r o v i d i n g me d i c a l ab o r t i o n in l o w-re s o u r c e settings: an introductory
More information6.1 Contraceptive Knowledge and Practices of Women Requesting Medical Termination of Pregnancy
6. UNSAFE ABORTIONS Complications from unsafe abortions if untreated, could lead to morbidity or death. The best way to prevent unsafe abortions is to reduce the unmet need for contraception and make safe
More informationInduced Abortion. Dr. Anan Sacdpraseuth Mahosot Hospital
Induced Abortion Dr. Anan Sacdpraseuth Mahosot Hospital GFMER - WHO - UNFPA - LAO PDR Training Course in Reproductive Health Research Vientiane, 26 November 2009 Induced Abortion Introduction 40 to 60
More informationDrug-Induced or Medical Abortion
Chapter 8 Drug-Induced or Medical Abortion Since 1985, when the drug RU-486 was introduced by the French pharmaceutical company, Roussel-Uclef, women have had an alternative to surgical abortion. RU-486
More informationNowrosjee Wadia Maternity Hospital
6. UNSAFE ABORTIONS The family planning programme of India is targeting towards providing a wide range of contraceptive choices to eligible couples with the ultimate objective of decreasing the unwanted
More informationMEDICAL abortion is the use of pills to
www.rhm-elsevier.com A 2005 Reproductive Health Matters. All rights reserved. Reproductive Health Matters 2005;13(26):20 24 0968-8080/05 $ see front matter PII: S0968-8080(05)26212-2 FEATURES Medical Abortion:
More informationALTERNATIVE TREATMENT PLAN AND CONSENT FOR MEDICAL ABORTION WITH MIFEPREX (MIFEPRISTONE) AND MISOPROSTOL
ALTERNATIVE TREATMENT PLAN AND CONSENT FOR MEDICAL ABORTION WITH MIFEPREX (MIFEPRISTONE) AND MISOPROSTOL The FDA gave its approval status to Mifepristone in 1996 based on research up to that time. Extensive
More informationFrequently Asked Questions (FAQ) for Medical Abortion
Frequently Asked Questions (FAQ) for Medical Abortion 1. What is medical abortion (MA)? MA is the use of one or more medications to terminate or end a pregnancy. Medical abortion is most effective when
More informationPreventing unsafe abortion
Preventing unsafe abortion Fact sheet N 388 March 2014 Key facts Around 22 million unsafe abortions are estimated to take place worldwide each year, almost all in developing countries. Deaths due to unsafe
More informationORIGINAL RESEARCH ARTICLE. Introduction Medical abortion using mifepristone combined
ORIGINAL RESEARCH ARTICLE Low-Dose Mifepristone 200 mg and Vaginal Misoprostol for Abortion Eric A. Schaff,* Steven H. Eisinger,* Lisa S. Stadalius, Peter Franks,* Bernard Z.Gore, and Suzanne Poppema The
More informationFacts for Women Termination of pregnancy, abortion, or miscarriage management
Patient Education Facts for Women Termination of pregnancy, abortion, or miscarriage management This handout answers common questions about miscarriage management and the termination of a pregnancy, also
More informationMedical abortion in early pregnancy
9 Introduction CHAPTER 9 Medical abortion in early pregnancy Mitchell D. Creinin MD, and Kristina Gemzell Danielsson MD, PhD LEARNING POINTS The standard or classic regimen of mifepristone 600 mg followed
More informationManagement of Side Effects and Complications in Medical Abortion: A Guide for Triage and On-Call Staff
Management of Side Effects and Complications in Medical Abortion: A Guide for Triage and On-Call Staff Managing daytime and after-hours calls from medical abortion patients is an important component of
More informationInfection after medical abortion: a review of the literature
Contraception 70 (2004) 183 190 Review article Infection after medical abortion: a review of the literature Caitlin Shannon, L. Perry Brothers, Neena M. Philip, Beverly Winikoff* Gynuity Health Projects,
More informationFamily Planning Curriculum
Family Planning Curriculum University of Alabama at Birmingham Department of Obstetrics and Gynecology Module 1: Introduction Incidence of unintended pregnancy and abortion Safety of abortion, morbidity
More informationPROTOCOL RECOMMENDATIONS FOR USE OF METHOTREXATE AND MISOPROSTOL IN EARLY ABORTION
PROTOCOL RECOMMENDATIONS FOR USE OF METHOTREXATE AND MISOPROSTOL IN EARLY ABORTION INTRODUCTION: Both methotrexate and misoprostol have been approved by the U.S. Food and Drug Administration (FDA) for
More informationAbortion is the termination of a pregnancy before the. Original Article. Paudel N 1 1 INTRODUCTION
, Vol. 1,. 2, Issue 2, Oct.-Dec., 2012 Original Article Paudel N 1 1 Lecturer, B.Sc. Nursing Programme, Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal Abstract Background: Medical abortion
More informationInduction of Abortion in the First Trimester by Misoprostol or Misoprostol With Letrozole
Biotech Health Sci. 2015 August; 2(3): e29562. Published online 2015 August 24. DOI: 10.17795/bhs-29562 Research Article Induction of Abortion in the First Trimester by Misoprostol or Misoprostol With
More informationChapter 10. When Abortion Fails
Chapter 10 When Abortion Fails Occasionally abortion fails, especially when it is drug induced. When this happens, either a second D&C or a more serious surgery may be attempted. The other alternative
More informationMifepristone in Abortion Care
Mifepristone in Abortion Care Courtney Schreiber, M.D., 1,3 and Mitchell Creinin, M.D. 2,3 ABSTRACT With the addition of a prostaglandin analog, mifepristone allows for successful outpatient termination
More informationTHE DIFFERENCE BETWEEN THE MORNING-AFTER PILL AND THE ABORTION PILL
THE DIFFERENCE BETWEEN THE MORNING-AFTER PILL AND There has been considerable public confusion about the difference between the morning-after pill and the abortion pill because of misinformation disseminated
More informationTermination of pregnancy. A resource for health professionals. November 2005. Excellence in women s health
Termination of pregnancy A resource for health professionals November 2005 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists Excellence in women s health This is a publication
More informationFrequently asked clinical questions about medical abortion
Frequently asked clinical questions about medical abortion WHO Library Cataloguing-in-Publication Data Frequently asked clinical questions about medical abortion. On 1 5 November 2004, in Bellagio, Italy,
More informationKey Words: Self Medication, Abortion Pill, Women Health, Medical Abortion, Unsafe abortion.
Research Article Self Medication of Abortion Pill: Women s Health in Jeopardy Rajal V Thaker *, Kruti J Deliwala**, Parul T Shah*** *Associate Professor, **Assistant Professor, ***Professor Department
More informationMisoprostol for Treatment of Incomplete Abortion: An Introductory Guidebook
Misoprostol for Treatment of Incomplete Abortion: An Introductory Guidebook MISOPROSTOL FOR TREATMENT OF INCOMPLETE ABORTION: AN INTRODUCTORY GUIDEBOOK CONTRIBUTORS: JENNIFER BLUM, JILLIAN BYNUM, RASHA
More informationThe authors: ISBN: 978-2-9553002-0-6 Copyright: Affinités Santé, 2015
The authors: - Kristina GEMZELL-DANIELSSON, MD, PhD, gynaecologist-obstetrician, Division of Obstetrics and Gynaecology, Department of Women s and Children s Health, Karolinska Institutet, Karolinska University
More informationThapaliya Kailash et al. Int. Res. J. Pharm. 2015, 6 (6) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Research Article USE OF MIFEPRISTONE AND MISOPROSTOL COMBINATION ON ABORTION IN FIRST TRIMESTER PREGNANCY AT GOVERNMENT HOSPITAL
More informationThe effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13 22 weeks gestation
Human Reproduction Vol.20, No.11 pp. 3072 3077, 2005 Advance Access publication July 29, 2005. doi:10.1093/humrep/dei216 The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone
More informationNew approaches to management of early pregnancy loss (miscarriage) Larry Leeman MD MPH UNM MCH Resident School September 5, 2012
New approaches to management of early pregnancy loss (miscarriage) Larry Leeman MD MPH UNM MCH Resident School September 5, 2012 Disclosure Statement No conflicts of interest Misoprostol is not FDA approved
More informationFirst-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review
Contraception 87 (2013) 26 37 Review article First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review Elizabeth G. Raymond a,, Caitlin Shannon b, Mark A. Weaver c,
More informationearly MEDICAL ABORTION A PRACTICAL GUIDE FOR HEALTHCARE PROFESSIONALS
introduction: disparities in the abortion situation in Europe early MEDICAL ABORTION A PRACTICAL GUIDE FOR HEALTHCARE PROFESSIONALS Dr Christian FIALA Dr Sharon CAMERON Dr Teresa-Alexandra CARMO-BOMBAS
More informationAssessment and management of miscarriage
Assessment and management of miscarriage Dawn Miller is a Senior Lecturer in Women s Health at the Dunedin School of Medicine, University of Otago. She is also a doctor at Family Planning, Dunedin, and
More informationEvaluation of cardiotocographic and cord blood changes in induced labor with dinoprostone and misoprostol
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Pandey K et al. Int J Reprod Contracept Obstet Gynecol. 2014 Mar;3(1):199-203 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationWHAT YOU SHOULD KNOW ABOUT ABORTION
WHAT YOU SHOULD KNOW ABOUT ABORTION It is the public policy of the state of Idaho to prefer live childbirth over abortion: "The Supreme Court of the United States having held that the states have a "profound
More informationA Quick Reference Guide for Clinicians
A Quick Reference Guide for Clinicians Association of Reproductive Health Professionals This Quick Reference Guide for Clinicians presents a summary of scientific information about manual vacuum aspiration
More informationWHAT YOU SHOULD KNOW ABOUT ABORTION
WHAT YOU SHOULD KNOW ABOUT ABORTION It is the public policy of the state of Idaho to prefer live childbirth over abortion: "The Supreme Court of the United States having held that the states have a "profound
More informationInformation for you Abortion care
Information for you Abortion care Published in February 2012 This information is for you if you are considering having an abortion. It tells you: how you can access abortion services the care you can expect
More informationNovaSure: A Procedure for Heavy Menstrual Bleeding
NovaSure: A Procedure for Heavy Menstrual Bleeding The one-time, five-minute procedure Over a million women 1 have been treated with NovaSure. NovaSure Endometrial Ablation (EA) is the simple, one-time,
More informationFirst-trimester medical abortion service in Hong Kong
Medical PRACTICE First-trimester medical abortion service in Hong Kong Sue ST Lo *, PC Ho A B S T R A C T Research on medical abortion has been conducted in Hong Kong since the 1990s. It was not until
More informationSaving women s lives: the health impact of unsafe abortion
Saving women s lives: the health impact of unsafe abortion - worldwide and in emergency settings SRHR in Emergencies: from policy commitment to implementation, DGD, Brussels, 18 October 2012 Thérèse Delvaux,
More informationHaving an early medical abortion
Having an early medical abortion Patient information PAGE 2 OF 15 Early medical abortion The following information is for women intending to have an abortion at Gynaecology Centres Australia. More detailed
More informationthe abortion pill by David Hager, M.D.
the abortion pill by David Hager, M.D. A positive pregnancy test is one of the most life-changing moments for a woman. Never is it more important to base your decisions on accurate information. Try to
More informationImproving technologies to reduce abortion-related morbidity and mortality
International Journal of Gynecology and Obstetrics 85 Suppl. 1 (2004) S73 S82 Improving technologies to reduce abortion-related morbidity and mortality K. Rogo* The World Bank, J8-805, 1818 H Street NW,
More informationALTERNATIVE TO SURGICAL EVACUATION OF UTERUS: MISOPROSTOL FOR POST-ABORTION CARE
ORIGINAL ARTICLE ALTERNATIVE TO SURGICAL EVACUATION OF UTERUS: MISOPROSTOL FOR POST-ABORTION CARE ABSTRACT KHADIJA BANO, TALAT, SAMREEN IQBAL Objective Study design Place & Duration of study Patients and
More informationAnnotated Bibliography on Mifepristone Medical Abortion
Annotated Bibliography on Mifepristone Medical Abortion APPROVED AND EVIDENCE-BASED REGIMENS UP TO 9 WEEKS (1 ST TRIMESTER) Shannon C, Weibe, E., Guilbert E, Dunn S, Sheldon WR, Winikoff B. Regimens of
More informationHandbook on Medical Methods of Abortion. by Government of Madhya Pradesh and Ipas to expand access to new technologies for safe abortion
Handbook on Medical Methods of Abortion by Government of Madhya Pradesh and Ipas to expand access to new technologies for safe abortion 2013 MMA Reference Manual.indd 1 05/07/13 5:56 PM About Ipas Ipas
More informationTermination of pregnancy: Information and legal obligations for medical practitioners
Termination of pregnancy: Information and legal obligations for medical practitioners Contents 1. Introduction 3 Aim of document 3 2. Abortion and the law (summary) 6 Informed consent 6 3. Timing of referral
More informationTERMINATION OF PREGNANCY- MEDICAL
TERMINATION OF PREGNANCY- MEDICAL Information Leaflet Your Health. Our Priority. Page 2 of 8 You have been offered a medical termination of pregnancy using mifepristone. You will have been given some verbal
More informationBUTTE COUNTY PUBLIC HEALTH DEPARTMENT POLICY & PROCEDURE
BUTTE COUNTY PUBLIC HEALTH DEPARTMENT POLICY & PROCEDURE SUBJECT: Pregnancy Testing and Counseling Protocol P&P # APPROVED BY: EFFECTIVE DATE: Mark Lundberg MD Health Officer REVISION DATE: 2/20/2010 Phyllis
More informationSafe & Unsafe. abortion
Safe & Unsafe Facts About abortion WHAT IS THE DIFFERENCE BETWEEN UNSAFE AND SAFE ABORTION? What is unsafe abortion? Unsafe abortion is a procedure for terminating an unplanned pregnancy either by a person
More informationSafe abortion: technical and policy guidance for health systems. Second edition
Safe abortion: technical and policy guidance for health systems Second edition Safe abortion: technical and policy guidance for health systems Second edition Acknowledgements WHO is grateful for the technical
More informationPatient information leaflet for Termination of Pregnancy (TOP) / Abortion
Patient information leaflet for Termination of Pregnancy (TOP) / Abortion Families Division Options available If you d like a large print, audio, Braille or a translated version of this leaflet then please
More informationEarly abortion services in the United States: a provider survey
Contraception 67 (2003) 287 294 Original research article Early abortion services in the United States: a provider survey Janie Benson a, *, Kathryn Andersen Clark b, Ann Gerhardt c, Lynne Randall d, Susan
More informationGuidelines for the Use of Mifepristone for Medical Abortion in New Zealand Contents
Guidelines for the Use of Mifepristone for Medical Abortion in New Zealand Contents Abbreviations used in this document...6 1. Introduction...7 2. Background...7 2.1 Approval of mifepristone (Mifegyne
More informationHigh quality follow up support and care
High quality follow up support and care How do you think the benefits of high quality follow up care? Client satisfaction Safe and effective continuation of the method What are the tasks involved in routine
More informationFEATURE. Adolescent Girls and Abortion
Adolescent Girls and Abortion Lawren Wellisch, MD; and Julie Chor, MD, MPH Abstract Abortion is an extremely common procedure in the United States, with approximately 2% of women having an abortion before
More informationComparison of Sublingual and Vaginal Misoprostol for Termination of Early Pregnancy Failure: A Randomized Controlled Trial
Thai Journal of Obstetrics and Gynaecology July 2014, Vol. 22, pp. 128-136 OBSTETRICS Comparison of Sublingual and Vaginal Misoprostol for Termination of Early Pregnancy Failure: A Randomized Controlled
More informationInterrupted Pregnancy Coding
Interrupted Pregnancy Coding American College of Obstetricians and Gynecologists Terry Tropin, RHIA, CPC, CCS-P, ACS-OB, PCS Content Development Expert, DecisionHealth ACOG Committee on Coding and Nomenclature
More informationEach year more than 75 million women worldwide experience an unintended
Inside Pregnancy Diagnostics... 7 OUT Feature Article New Approaches to Early Abortion Each year more than 75 million women worldwide experience an unintended pregnancy. 1 For many of these women, contraception
More informationCelebrating 10 years. Rational Assessment of Drugs and Research. August 2013 TIMELY, INDEPENDENT INFORMATION ABOUT NEW DRUGS
Rational Assessment of Drugs and Research www.npsradar.org.au August 2013 TIMELY, INDEPENDENT INFORMATION ABOUT NEW DRUGS Celebrating 10 years Mifepristone (Mifepristone Linepharma) followed by misoprostol
More informationINTRODUCTION OF MEDICAL ABORTION IN GHANA
INTRODUCTION OF MEDICAL ABORTION IN GHANA Emmanuel Osei Kuffour 1, Selina F. Esantsi 1, Placide Tapsoba 1, Gloria Quansah- Asare 2, Ian Askew 3 Emmanuel Osei Kuffour PhD (abd); M&E Advisor, Population
More informationEARLY PREGNANCY LOSS A Patient Guide to Treatment
EARLY PREGNANCY LOSS A Patient Guide to Treatment You have a pregnancy that has stopped growing, or you have started to miscarry and the process has not completed. If so, there are four ways to manage
More informationEmergency contraception, including ellaone (based on FSRH/CEU Guidance)
Emergency contraception, including ellaone (based on FSRH/CEU Guidance) Dr Lynsey Dunckley Associate Specialist SRH Southampton Solent Sexual Health Conference Friday 25 th January 2013 Quiz! Which is
More informationCHLAMYDIA SCREENING IN WOMEN
CHLAMYDIA SCREENING IN WOMEN APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE What screening should be done? NCQA ACCEPTED CODES DOCUMENTATION
More informationAbnormal Uterine Bleeding FAQ Sheet
Abnormal Uterine Bleeding FAQ Sheet What is abnormal uterine bleeding? Under normal circumstances, a woman's uterus sheds a limited amount of blood during each menstrual period. Bleeding that occurs between
More informationabortion abortion abortion abortion abortion abortion abortion on abortio abortion ortion abortion abortion abortion abortion abortio
Abortion Your questions answered abortio bortion ion ortion on abortio 2 Are you pregnant but not sure you want to have the baby? Do you need more information about your pregnancy choices? Unplanned pregnancy
More informationMethods for Induced Abortion
CLINICAL GYNECOLOGIC SERIES: AN EXPERT S VIEW We have invited select authorities to present background information on challenging clinical problems and practical information on diagnosis and treatment
More informationPreconception Clinical Care for Women Medical Conditions
Preconception Clinical Care for Women All women of reproductive age are candidates for preconception care; however, preconception care must be tailored to meet the needs of the individual. Given that preconception
More informationSublingual misoprostol versus standard surgical care for treatment of incomplete abortion. in five sub-saharan African countries
Sublingual misoprostol versus standard surgical care for treatment of incomplete abortion in five sub-saharan African countries Authors: Tara Shochet PhD, MPH, Gynuity Health Projects 15 E. 26 th St. Suite
More informationThe following chapter is called "Follow-ups with a Positive or a Negative Pregnancy Test".
Slide 1 Welcome to chapter 7. The following chapter is called "Follow-ups with a Positive or a Negative Pregnancy Test". The author is Professor Pasquale Patrizio. Slide 2 This chapter has the following
More informationAn Overview of Abortion in the United States. Guttmacher Institute January 2014
An Overview of Abortion in the United States Guttmacher Institute January 2014 Objectives Provide an overview of unintended pregnancy and abortion in the United States. Review the incidence of pregnancy
More informationSTANDARD APRN PROTOCOL FOR IUD INSERTION: Levonorgestrel (LNG) Releasing Intrauterine System
STANDARD APRN PROTOCOL FOR IUD INSERTION: Levonorgestrel (LNG) Releasing Intrauterine System DEFINITION The LNG-releasing intrauterine systems (Mirena, Liletta and Skyla ) are on the market. The LNG-releasing
More informationMigration of an intrauterine contraceptive device to the sigmoid colon: a case report
The European Journal of Contraception and Reproductive Health Care 2003;8:229 232 Case Report Migration of an intrauterine contraceptive device to the sigmoid colon: a case report Ü. S. nceboz, H. T. Özçakir,
More informationHormonal Oral Contraceptives: An Overview By Kelsie Court. A variety of methods of contraception are currently available, giving men and
Hormonal Oral Contraceptives: An Overview By Kelsie Court A variety of methods of contraception are currently available, giving men and women plenty of options in choosing a method suitable to his or her
More informationTherapeutic termination of pregnancy
Therapeutic termination of pregnancy Document title: Document number: Document supplement Therapeutic termination of pregnancy MN13.21-V1-R18 Publication date: April 2013 Review date: April 2018 Amendments:
More informationPrediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in Cases of Habitual Abortions
Prediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in * (MBChB, FICMS, CABOG) **Sawsan Talib Salman (MBChB, FICMS, CABOG) ***Huda Khaleel Ibrahim (MBChB) Abstract Background: - Although
More informationAbortion in Practice. A guide for GPs
Abortion in Practice A guide for GPs contents introduction four By British Pregnancy Advisory Service (BPAS) Medical Director part one pre-abortion five Who can be referred to BPAS? How to refer Other
More informationUltrasound in the First Trimester of Pregnancy. Elizabeth Lipson, HMS III
Ultrasound in the First Trimester of Pregnancy Elizabeth Lipson, HMS III First Trimester Sonography Localization of Gestational Sac Intrauterine vs. ectopic Identification of abnormalities Embryonic demise
More informationEctopic pregnancy and miscarriage
Ectopic pregnancy and miscarriage Diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage Issued: December 2012 NICE clinical guideline 154 guidance.nice.org.uk/cg154 NHS
More informationCrohn's disease and pregnancy.
Gut, 1984, 25, 52-56 Crohn's disease and pregnancy. R KHOSLA, C P WILLOUGHBY, AND D P JEWELL From the Gastroenterology Unit, Radcliffe Infirmary, Oxford SUMMARY Infertility and the outcome of pregnancy
More informationArtificial insemination with donor sperm
Artificial insemination with donor sperm Ref. 123 / 2009 Reproductive Medicine Unit Servicio de Medicina de la Reproducción Gran Vía Carlos III 71-75 08028 Barcelona Tel. (+34) 93 227 47 00 Fax. (+34)
More informationUnderstanding Medical Abortion Policy, Politics, and Women s Health
Policy Matters #3 Understanding Medical Abortion Policy, Politics, and Women s Health S. Marie Harvey, Christy A. Sherman, Sheryl Thorburn Bird, and Jocelyn Warren Research Program on Women s Health Center
More informationIORG. International Organizations Research Group. Briefing Paper Number 10 November 7, 2012
Briefing Paper Number 10 November 7, 2012 Eleven Problems with the 2012 WHO Technical Guidance on Abortion By Susan Yoshihara, Ph.D. and Rebecca Oas, Ph.D. E W Y O R K W A S H I N G T O N, D C Eleven Problems
More informationPost-Coital Hormonal Contraception Instructions for Use of Plan B, Plan B One-Step, Next Choice One Dose, My Way, Generic Levonorgestrel and Ella
Post-Coital Hormonal Contraception Instructions for Use of Plan B, Plan B One-Step, Next Choice One Dose, My Way, Generic Levonorgestrel and Ella Several options for emergency birth control exist for women
More informationIMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products
Dear Healthcare Provider: Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) has been mandated by the FDA (Food and Drug Administration) due to postmarketing reports showing that exposure to
More informationSouth Dakota Task Force to Study Abortion Pierre, South Dakota September 21, 2005
South Dakota Task Force to Study Abortion Pierre, South Dakota September 21, 2005 Section III. : The review and exposition of the body of medical, psychological, and sociological knowledge that has accumulated
More informationInformation on termination of pregnancy (abortion) A series of information leaflets on termination of pregnancy services in Greater Glasgow & Clyde
Information on termination of pregnancy (abortion) A series of information leaflets on termination of pregnancy services in Greater Glasgow & Clyde Your first doctors appointment The assessment clinic
More informationMedical termination of pregnancy and subsequent adoption of contraception
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Shankaraiah RH et al. Int J Reprod Contracept Obstet Gynecol. 2013 Sep;2(3):367-371 www.ijrcog.org pissn 2320-1770 eissn
More informationSPECIAL EDITION 3 SUMMER 2009 ISSN ABORTION AND CLINICAL PRACTICE. Papers from the bpas conference, London, 25-26 June 2008
SPECIAL EDITION AbortionReview SPECIAL EDITION 3 SUMMER 2009 ISSN ABORTION AND CLINICAL PRACTICE Papers from the bpas conference, London, 25-26 June 2008 Inside this issue: Issues in Early Medical Abortion
More informationOPTIONS GUIDE TO EARLY ABORTION
THE EARLY OPTIONS GUIDE TO EARLY ABORTION Understanding Options oeearlyoptions For Early Abortion Table of Contents Why This Guide 1 Making Your Decision..3 Understanding Early Pregnancy.6 Early Abortion
More informationWHO Recommendations for the Prevention of Postpartum Haemorrhage Results from a WHO Technical Consultation October 18-20, 2006
WHO Recommendations for the Prevention of Postpartum Haemorrhage Results from a WHO Technical Consultation October 18-20, 2006 Panel Presentation: M E Stanton, USAID; R Derman, UM/KC; H Sangvhi, JHPIEGO;
More informationLorem Ipsum. Abortion: What can it do to a woman? Design: Issues in Health Aili Middleton
Lorem Ipsum Abortion: What can it do to a woman? Design: Issues in Health Aili Middleton Lorem Ipsum 2 Basic Information & Process Abortion is the premature termination of a pregnancy. It can be induced
More information